Supernus Pharmaceuticals Inc expected to post earnings of 24  cents a share - Earnings Preview

Supernus Pharmaceuticals

29/04/2022 13:50

* Supernus Pharmaceuticals Inc  SUPN.OQ   SUPN.O  is
expected
to show a rise in quarterly revenue when it reports  results on
May 3 (estimated). 
    * The Rockville Maryland-based  company is expected to
report  a
14.9% increase in revenue to $150.471 million from $130.93
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Supernus
Pharmaceuticals
Inc is for earnings of 24 cents per share. For the same quarter
last year, the company reported earnings of 11 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 3.4%
in the last three months. ​
    * Wall Street's median 12-month price target for Supernus
Pharmaceuticals Inc is $35​, above​ its last closing price
of $28.42. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  0.29        0.24       0.04      Missed  -83.1
 Sep. 30 2021  0.23        0.23       0.40      Beat    72
 Jun. 30 2021  0.20        0.20       0.43      Beat    117.7​
 Mar. 31 2021  0.24        0.24       0.11      Missed  -54.6
 ​​Dec.        0.59        0.52       0.57      Beat    10.1
 31 2020                                                
 Sep. 30 2020  0.32        0.30       0.74      Beat    148.7​
 Jun. 30 2020  0.41        0.42       0.65      Beat    54.8
 Mar. 31 2020  0.27        0.28       0.40      Beat    41.8
 This summary was machine generated April 29 at 12:50 GMT.  All
figures in US dollars  unless otherwise stated